Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

It’s easy to distinguish a healthy person from a person with advanced Parkinson’s: the Parkinson’s sufferer has large clumps of proteins in his or her brain cells. Scientists disagree, however, about the nature of these clumps. Some contend that they lead to the massive neuronal cell death and resulting movement disorders in Parkinson’s, others that the clumps are merely a byproduct of the disease – and some scientists contend that the clumps are actually protective, sequestering toxic proteins so they can’t hurt the cell. Mounting evidence points to the last possibility.

Existing research already suggests that the biggest clumps, known as inclusions, are helpful. Cells that form clumps of the mutant Huntington protein, for example, survive longer than clump-free cells. Now MIT scientists have discovered a compound that increases clumps in cell models of Huntington’s and Parkinson’s disease and makes the cells healthier. Scientists aren’t sure how the compound works, but they think it might be helping cells get rid of toxic forms of the proteins floating around in the cell by isolating them into clumps.

“Using a compound to promote inclusions is a novel therapeutic approach,” says Ruth Bodner, an MIT neuroscientist who led the research.

Many neurodegenerative diseases are linked to misshapen proteins, which tend to stick together, aggregating into blobs of tens, hundreds, thousands, or more, which are eventually visible in diagnostic tests. These proteins disrupt cellular processes and eventually lead to cell death. Unfortunately, scientists don’t know exactly at what stage of aggregation the proteins are most harmful or how they kill cells.

In a large-scale drug screen published today in the Proceedings of the National Academy of Sciences, Bodner, MIT biology professor David Housman, and colleagues studied cells expressing mutant proteins implicated in Parkinson’s disease and Huntington’s disease. To their surprise, they identified a compound, called B2, which boosted the number of clumps as well as the health of the cells; Parkinson’s cells that normally would have died survived when given B2. And Huntington’s cells treated with the compound had better functioning proteosomes – cellular “garbage cans” that are often dysfunctional in the disease.

The findings could provide a novel approach to drug development. “If you develop a molecule that is truly targeting the cellular pathway by which cells recognize malformed proteins and try to deal with them, I think it could have broad implications,” says Steven Finkbeiner, a neurologist at the University of California, San Francisco. “A number of other neurodegenerative and non-neural diseases are characterized by abnormal proteins folding,” he adds.

1 comment. Share your thoughts »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me